• Price (EUR)424.00
  • Today's Change-4.00 / -0.93%
  • Shares traded0.00
  • 1 Year change-8.32%
  • Beta--
Data delayed at least 15 minutes, as of Jun 08 2023 07:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.

  • Revenue in USD (TTM)160.67bn
  • Net income in USD6.21bn
  • Incorporated2001
  • Employees102.30k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
ELV:NYQ since
Blue Cross & Blue Shield of LouisianaAnnounced23 Jan 202323 Jan 2023Announced-2.76%--
BioPlus Specialty Pharmacy Services LLCAnnounced09 Nov 202209 Nov 2022Announced-12.08%--
Data delayed at least 15 minutes, as of Jun 08 2023 21:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.